Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2019 / Industry Influencers / Richard Johnson

Richard Johnson

President and Chief Executive Officer, Parenteral Drug Association

  • Profile

Meet Richard Johnson

“Day-to-day, I never forget that the ultimate users of pharmaceutical products are people, including our families, friends and ourselves. Many of the biggest impacts on modern life have come through better prevention and treatment of diseases. Life expectancy and quality of life have dramatically changed in my lifetime, and any contribution that I can make is an intrinsic good! But I would like to see more focus on improving the manufacturing of pharma products. The predominant business model is to focus on new therapies, but without a corresponding focus on improving the manufacturing of these products, many patients will not receive the quality of pharma products they need. Exciting new therapies are coming into the market: cell and gene therapies, and integrated drug, device, diagnostic products. We must also continue to focus on improving the manufacture of existing therapies, that serve the vast majority of patients worldwide.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.